Catheter to Aid Treatment of Vascular Occlusions

The new family of catheters is based on the Frontrunner X39 coronary CTO catheter, which utilizes a proprietary blunt microdissection technology to improve a doctor's ability to cross CTOs. As a result, lesions that were considered untreatable with existing percutaneous methods can now be considered in light of the performance of the Frontrunner XP. The XP can be delivered through a 6 French guide catheter and incorporates a more flexible shaft to optimize delivery performance.

"There are a multitude of new therapies evolving to treat the enormous population affected by peripheral vascular disease,” stated Phil Hopper, president and CEO of LuMend (Redwood, City, CA, USA), which developed the XP. "However, in order for these emerging technologies to be successful, a conventional guide wire must first be placed across the CTO. This is where the Frontrunner XP adds tremendous value.”




Related Links:
LuMend